ClinicalTrials.gg
CompletedNCT00839163Updated Sep 7, 2023

Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)

A Phase 2 interventional study of Xarelto (Rivaroxaban, BAY59-7939) and Xarelto (Rivaroxaban, BAY59-7939) in Venous Thrombosis and Deep Vein Thrombosis, sponsored by Bayer. Completed at 110 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
613
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing rivaroxaban in Venous Thrombosis — 5 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Venous Thrombosis.

Enrollment
11th of 36
613 · median 120
Started
2004
the only one that year
Phase 2
4 of 36
none open now
Registered
4th of 36
by date
Lead sponsor
11 of 36
Bayer

Among the 36 studies testing rivaroxaban in Venous Thrombosis, this one is the 11th largest by enrollment, is the only one that started in 2004, is one of 4 in phase 2, and was the 4th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 36 studies testing rivaroxaban in Venous Thrombosis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing rivaroxaban in Venous Thrombosis, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety and efficacy of the licensed drug enoxaparin and a licensed oral vitamin K-antagonist and to find the optimal dose of BAY59-7939 for the anticipated phase III trials and for the future clinical use.

03

Conditions studied

  • Venous Thrombosis
  • Deep Vein Thrombosis

Keywords

  • Embolism and Thrombosis
  • Pulmonary embolism
  • Embolism
  • Thrombosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acute symptomatic proximal deep vein thrombosis

Exclusion criteria

Exclusion Criteria:

  • to comparator drugs
  • Symptomatic Pulmonary embolism
  • Conditions with increased bleeding risk
  • Unstable patients with reduced
  • Severe renal impairment
  • Impaired liver function
  • Strong CYP 3A4 inhibitors
  • aggregation inhibitors (exception: ASA up to 500mg) therapy with anticoagulants or fibrinolytics
  • NSAIDs with half-life > 17 hours
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
613 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Xarelto (Rivaroxaban, BAY59-7939)

  • Experimental
    Arm 2

    Drug: Xarelto (Rivaroxaban, BAY59-7939)

  • Experimental
    Arm 3

    Drug: Xarelto (Rivaroxaban, BAY59-7939)

  • Experimental
    Arm 4

    Drug: Xarelto (Rivaroxaban, BAY59-7939)

  • Active comparator
    Arm 5

    Drug: Enoxaparin/Vitamin K-Antagonist

Interventions

  • 10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).

  • 20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).

  • 30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).

  • 40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).

  • DrugEnoxaparin/Vitamin K-Antagonist

    Drug pages: Enoxaparin · Vitamin K Antagonist

    Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days

06

What researchers measure

Primary outcomes

  1. Response to treatment as determined by a Complete Compression Ultra sound (CCUS)

    Time frame: 21 days

Secondary outcomes

  1. Response to treatment as determined by a Complete Compression Ultrasound (CCUS) and perfusion lung scan

    Time frame: Day 21

  2. Response to treatment and residual vein diameter as assessed by Complete Compression Ultrasound (CCUS)

    Time frame: Day 84

  3. Incidence of symptomatic and confirmed recurrence or extension of Deep Vein Thrombosis (DVT)

    Time frame: Day 1-84

  4. Composite endpoint of symptomatic and confirmed recurrence and extension of Deep Vein Thrombosis (DVT) and symptomatic Pulmonary Embolism (PE) (nonfatal DVT and/or nonfatal PE) and deaths during the 3 months treatment period

    Time frame: Day 1-84

  5. Incidence of symptomatic and confirmed recurrence and extension of Deep Vein Thrombosis (DVT) and symptomatic Pulmonary Embolism (PE) within 30 days after stop of treatment with study drug

    Time frame: Day 1-114

07

Study locations

110 sites
  • Sydney, New South Wales 2217, Australia
  • Adelaide, South Australia 5011, Australia
  • Adelaide, South Australia 5042, Australia
  • Melbourne, Victoria 3128, Australia
  • Melbourne, Victoria 3135, Australia
  • Melbourne, Victoria 3181, Australia
  • Perth, Western Australia 6000, Australia
  • Graz, Steiermark 8036, Austria
  • Wien, 1090, Austria
  • Wien, 1171, Austria
  • Duffel, 2570, Belgium
  • Leuven, 3000, Belgium
  • Sao Paulo, SP 04544 000, Brazil
  • São Paulo, SP 01323-001, Brazil
  • Vancouver, British Columbia V6Z 1Y6, Canada
  • Hamilton, Ontario L8L 2X2, Canada
  • Hamilton, Ontario L8N 4A6, Canada
  • North Bay, Ontario P1B 5A4, Canada
  • Oshawa, Ontario L1G 2B9, Canada
  • Ottawa, Ontario K1Y 4E9, Canada
  • Sudbury, Ontario P3E 3B5, Canada
  • Toronto, Ontario M3N 1N1, Canada
  • Windsor, Ontario N8X 3V6, Canada
  • Montreal, Quebec H2W 1T8, Canada
  • Montreal, Quebec H3T 1M5, Canada
  • Barranquilla, Colombia
  • Bogotá, Colombia
  • Medellín, Colombia
  • Brno, 656 91, Czechia
  • Kladno, 27259, Czechia
  • Ostrava, 728 80, Czechia
  • Plzen, 30599, Czechia
  • Praha 10, 10034, Czechia
  • Praha 2, 12808, Czechia
  • Praha 6, 169 02, Czechia
  • Heidelberg, Baden-Württemberg 69115, Germany
  • Karlsbad, Baden-Württemberg 76307, Germany
  • Mannheim, Baden-Württemberg 68167, Germany
  • München, Bayern 80336, Germany
  • Darmstadt, Hessen 64276, Germany
  • Bergisch Gladbach, Nordrhein-Westfalen 51429, Germany
  • Paderborn, Nordrhein-Westfalen 33098, Germany
  • Dresden, Sachsen 01307, Germany
  • Berlin, 10365, Germany
  • Berlin, 10787, Germany
  • Budapest, 1115, Hungary
  • Debrecen, 4032, Hungary
  • Pecs, 7624, Hungary
  • Szentes, 6600, Hungary
  • Afula, 18101, Israel
  • Ashkelon, 78306, Israel
  • Haifa, 31096, Israel
  • Holon, 58100, Israel
  • Jerusalem, 91120, Israel
  • Kfar Saba, 44281, Israel
  • Tel Aviv, 64239, Israel
  • Rozzano, Milano 20089, Italy
  • Bologna, 40138, Italy
  • Milano, 20142, Italy
  • Milano, 20162, Italy
  • Padova, 35128, Italy
  • Palermo, 90129, Italy
  • Perugia, 06122, Italy
  • Piacenza, 29100, Italy
  • Reggio Emilia, 42100, Italy
  • Varese, 21100, Italy
  • Arnhem, 6815 AD, Netherlands
  • Den Bosch, 5211 RB, Netherlands
  • Den Haag, 2512 VA, Netherlands
  • Dirksland, 3247 BW, Netherlands
  • Enschede, 7511 JX, Netherlands
  • Leidschendam, 2262 BA, Netherlands
  • Rotterdam, 3083 AN, Netherlands
  • Auckland, 0622, New Zealand
  • Auckland, 1023, New Zealand
  • Christchurch, 8011, New Zealand
  • Lima Cercado, LIMA 1, Peru
  • Lima, 01, Peru
  • Lima, 31, Peru
  • Bialystok, 15-276, Poland
  • Bytom, 41-902, Poland
  • Gdansk, 80-952, Poland
  • Katowice, 40-752, Poland
  • Lublin, 20-718, Poland
  • Olsztyn, 10-560, Poland
  • Poznan, 61-833, Poland
  • Warszawa, 02-097, Poland
  • Bloemfontein, Freestate 9300, South Africa
  • Pretoria, Gauteng 0084, South Africa
  • Pretoria, Gauteng 0157, South Africa
  • Pretoria, Gauteng PRETORIA, South Africa
  • Cape Town, Western Cape 7531, South Africa
  • Somerset West, Western Cape 7130, South Africa
  • Badalona, Barcelona 08916, Spain
  • Olot, Girona 17800, Spain
  • La Laguna, Tenerife 38320, Spain
  • Barcelona, 08036, Spain
  • Girona, 17007, Spain
  • Madrid, 28006, Spain
  • Madrid, 28007, Spain

Showing the first 100 of 110 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2009
First posted
Feb 9, 2009
Start
Mar 2004
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Last update
Sep 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00839163
Lead sponsor
Bayer
First posted
Feb 9, 2009
Start date
Mar 2004
Primary completion
Oct 2005
Completion
Oct 2005
Last update
Sep 7, 2023

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion